{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:13:53Z","timestamp":1764080033813,"version":"build-2065373602"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004162","name":"Meath Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001594","name":"Irish Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003840","name":"Irish Institute of Clinical Neuroscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jns.2024.123118","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:25:24Z","timestamp":1719926724000},"page":"123118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["von Willebrand factor antigen, von Willebrand factor propeptide and ADAMTS13 activity in TIA or ischaemic stroke patients changing antiplatelet therapy"],"prefix":"10.1016","volume":"463","author":[{"given":"D.R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.T.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.X.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.B.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Offiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.H.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123118_bb0005","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3389\/fimmu.2019.02884","article-title":"von Willebrand factor and platelet glycoprotein Ib: a Thromboinflammatory Axis in stroke","volume":"10","author":"Denorme","year":"2019","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.jns.2024.123118_bb0010","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2009-12-258780","article-title":"The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity","volume":"116","author":"de Groot","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/svn-2019-000302","article-title":"Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine","volume":"5","author":"Chen","year":"2020","journal-title":"Stroke Vasc Neurol"},{"issue":"4","key":"10.1016\/j.jns.2024.123118_bb0020","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2007-12-130740","article-title":"Basal secretion of von Willebrand factor from human endothelial cells","volume":"112","author":"Giblin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jns.2024.123118_bb0025","doi-asserted-by":"crossref","unstructured":"Furlan, M., Von Willebrand factor: molecular size and functional activity. Ann. Hematol., 1996. 72(6): p. 341\u2013348.","DOI":"10.1007\/s002770050184"},{"issue":"19","key":"10.1016\/j.jns.2024.123118_bb0030","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/jcp.25887","article-title":"A biophysical view on von Willebrand factor activation","volume":"233","author":"L\u00f6f","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jns.2024.123118_bb0040","doi-asserted-by":"crossref","first-page":"5620314","DOI":"10.1155\/2017\/5620314","article-title":"The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy","volume":"2017","author":"Gragnano","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0045","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2006-12-027698","article-title":"The growing complexity of platelet aggregation","volume":"109","author":"Jackson","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0050","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2011-02-306597","article-title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor","volume":"118","author":"Crawley","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jns.2024.123118_bb0055","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jns.2024.123118_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.blre.2014.04.003","article-title":"Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis","volume":"28","author":"Sonneveld","year":"2014","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179258","article-title":"Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease","volume":"12","author":"Denorme","year":"2017","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0070","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2006-12-027698","article-title":"The growing complexity of platelet aggregation","volume":"109","author":"Jackson","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jns.2024.123118_bb0075","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.bpj.2021.03.008","article-title":"Predicting pathological von Willebrand factor unraveling in elongational flow","volume":"120","author":"Kania","year":"2021","journal-title":"Biophys. J."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.thromres.2014.03.024","article-title":"High shear dependent von Willebrand factor self-assembly fostered by platelet interaction and controlled by ADAMTS13","volume":"133","author":"Kragh","year":"2014","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.jns.2024.123118_bb0085","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques","volume":"55","author":"Reininger","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.jns.2024.123118_bb0090","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/a-1334-8002","article-title":"Functional roles of the von Willebrand factor Propeptide","volume":"41","author":"Rawley","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jns.2024.123118_bb0100","doi-asserted-by":"crossref","unstructured":"Haberichter, S.L., von Willebrand factor propeptide: biology and clinical utility. Blood, 2015. 126(15): p. 1753\u20131761.","DOI":"10.1182\/blood-2015-04-512731"},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0105","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"Eikenboom","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jns.2024.123118_bb0110","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1182\/blood-2011-10-387548","article-title":"von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion","volume":"119","author":"Madabhushi","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jns.2024.123118_bb0115","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/j.1538-7836.2012.04797.x","article-title":"Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis","volume":"10","author":"Kanaji","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.jns.2024.123118_bb0120","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/01.STR.0000244767.39962.f7","article-title":"High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability","volume":"37","author":"Bongers","year":"2006","journal-title":"Stroke"},{"issue":"1\u20132","key":"10.1016\/j.jns.2024.123118_bb0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2014.10.035","article-title":"Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke","volume":"348","author":"McCabe","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2024.123118_bb0130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.thromres.2011.10.011","article-title":"Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases","volume":"129","author":"Habe","year":"2012","journal-title":"Thromb. Res."},{"issue":"7","key":"10.1016\/j.jns.2024.123118_bb0135","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/ene.12403","article-title":"Increased endothelial activation in recently symptomatic versus asymptomatic carotid artery stenosis and in cerebral microembolic-signal-negative patient subgroups","volume":"21","author":"Kinsella","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V94.1.179.413k18_179_185","article-title":"von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation","volume":"94","author":"van Mourik","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0145","first-page":"1002","article-title":"von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII)","volume":"80","author":"Vischer","year":"1998","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0038-1655973","article-title":"Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels","volume":"77","author":"Vischer","year":"1997","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0155","first-page":"164","article-title":"Von Willebrand factor propeptide in vascular disorders","volume":"86","author":"van Mourik","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0160","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1055\/s-0038-1656120","article-title":"von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality","volume":"77","author":"Catto","year":"1997","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0165","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/01.STR.0000126474.25720.3e","article-title":"Measurement of the antiplatelet effects of aspirin in cerebrovascular disease","volume":"35","author":"McCabe","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2024.123118_bb0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jns.2017.02.045","article-title":"Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes","volume":"375","author":"Tobin","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1538-7836.2010.04134.x","article-title":"Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke","volume":"9","author":"Hanson","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0180","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.atherosclerosis.2013.07.046","article-title":"Relationship of Von Willebrand factor with carotid artery and aortic arch calcification in ischemic stroke patients","volume":"230","author":"Sonneveld","year":"2013","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jns.2024.123118_bb0185","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/STROKEAHA.110.586289","article-title":"High von Willebrand factor levels increase the risk of stroke: the Rotterdam study","volume":"41","author":"Wieberdink","year":"2010","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0190","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2011-09-380618","article-title":"High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women","volume":"119","author":"Andersson","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0195","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","article-title":"Von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam study","volume":"36","author":"Sonneveld","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0200","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2141.2004.04983.x","article-title":"Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack","volume":"125","author":"McCabe","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.jns.2024.123118_bb0205","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-014-7362-3","article-title":"Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke","volume":"261","author":"Tobin","year":"2014","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00415-012-6684-2","article-title":"Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke","volume":"260","author":"Tobin","year":"2013","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0215","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09537100500235966","article-title":"Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke","volume":"17","author":"Zhao","year":"2006","journal-title":"Platelets"},{"year":"2020","series-title":"Profiles of von Willebrand Factor Antigen, von Willebrand Factor Propeptide and ADAMTS13 Activity in Patients with Carotid Stenosis and their Relationship with Cerebral micro-Embolic Status","author":"Murphy","key":"10.1016\/j.jns.2024.123118_bb0220"},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09537104.2020.1850670","article-title":"Profile of reticulated platelets in the early, subacute and late phases after transient ischemic attack or ischemic stroke","volume":"33","author":"Lim","year":"2022","journal-title":"Platelets"},{"issue":"5","key":"10.1016\/j.jns.2024.123118_bb0230","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000131083","article-title":"Guidelines for management of ischaemic stroke and transient ischaemic attack 2008","volume":"25","author":"European Stroke Organisation Executive","year":"2008","journal-title":"Cerebrovasc. Dis."},{"issue":"7","key":"10.1016\/j.jns.2024.123118_bb0235","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/jth.12277","article-title":"Increased platelet activation in early symptomatic vs. asymptomatic carotid stenosis and relationship with microembolic status: results from the platelets and carotid stenosis study","volume":"11","author":"Kinsella","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0240","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2141.2004.05137.x","article-title":"Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack","volume":"126","author":"McCabe","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00415-019-09550-3","article-title":"Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis","volume":"267","author":"Murphy","year":"2020","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0250","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0040-1715440","article-title":"von Willebrand factor antigen, von Willebrand factor Propeptide, and ADAMTS13 in carotid stenosis and their relationship with cerebral microemboli","volume":"121","author":"Murphy","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jns.2024.123118_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120334","article-title":"Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke","volume":"441","author":"Lim","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"Atiq","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jns.2024.123118_bb0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/jcls.jcls_92_17","article-title":"Pattern of von Willebrand factor in hypertensive patients in Lagos, Nigeria","volume":"15","author":"Ogbenna","year":"2018","journal-title":"J Clin Sci"},{"issue":"11","key":"10.1016\/j.jns.2024.123118_bb0275","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2024.123118_bb0280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"7","key":"10.1016\/j.jns.2024.123118_bb0285","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1073\/pnas.84.7.1955","article-title":"Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells","volume":"84","author":"Wagner","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0290","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2002-03-0814","article-title":"Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin","volume":"101","author":"Reiter","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0295","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2141.2004.05009.x","article-title":"Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease","volume":"126","author":"Mannucci","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jns.2024.123118_bb0300","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ajh.21739","article-title":"Analysis of von Willebrand factor structure by multimer analysis","volume":"85","author":"Ledford-Kraemer","year":"2010","journal-title":"Am J Haem"},{"issue":"7","key":"10.1016\/j.jns.2024.123118_bb0305","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1538-7836.2009.03453.x","article-title":"Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor","volume":"7","author":"Varadi","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0310","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1160\/th15-08-0620","article-title":"The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials","volume":"115","author":"Sahebkar","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jns.2024.123118_bb0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/BMI.S24353","article-title":"von Willebrand factor Propeptide: a potential disease biomarker not affected by ABO blood groups","volume":"10","author":"Marianor","year":"2015","journal-title":"Biomark. Insights"},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005468","article-title":"Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis","volume":"11","author":"Birnie","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0325","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1076029615625832","article-title":"Plasma ADAMTS13, von Willebrand factor (VWF), and VWF Propeptide profiles in patients with connective tissue diseases and antiphospholipid syndrome","volume":"23","author":"Habe","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0330","first-page":"35","article-title":"Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease","volume":"82","author":"Cattaneo","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2010.08333.x","article-title":"The impact of bleeding history, von Willebrand factor and PFA-100((R)) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD","volume":"151","author":"Castaman","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.jns.2024.123118_bb0340","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1538-7836.2011.04247.x","article-title":"Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients","volume":"9","author":"Hollestelle","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2024.123118_bb0345","first-page":"106","article-title":"Description of an in vitro platelet function analyzer\u2014PFA-100","volume":"21","author":"Kundu","year":"1995","journal-title":"Semin. Thromb. Hemost."},{"issue":"5","key":"10.1016\/j.jns.2024.123118_bb0350","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2010.08539.x","article-title":"Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study","volume":"152","author":"Tobin","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.jns.2024.123118_bb0355","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.17273","article-title":"Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation","volume":"192","author":"Ward","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.jns.2024.123118_bb0360","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jth.15409","article-title":"ADAMTS13 regulation of VWF multimer distribution in severe COVID-19","volume":"19","author":"Ward","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.jns.2024.123118_bb0365","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-Centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.jns.2024.123118_bb0370","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/jth.15830","article-title":"Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction","volume":"20","author":"Fogarty","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.jns.2024.123118_bb0375","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/jth.15490","article-title":"Persistent endotheliopathy in the pathogenesis of long COVID syndrome","volume":"19","author":"Fogarty","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.jns.2024.123118_bb0380","article-title":"Decreased ADAMTS13 activity during COVID-19 is associated with lower cognitive scores after recovery (P8-9.004)","volume":"102","author":"Gatchoff","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0385","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s43042-022-00354-1","article-title":"Dipyridamole and adenosinergic pathway in COVID-19: a juice or holy grail","volume":"23","author":"Al-kuraishy","year":"2022","journal-title":"Egypt J Med Hum Genet"},{"issue":"6","key":"10.1016\/j.jns.2024.123118_bb0390","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2174\/1381612826666201001125604","article-title":"Potential therapeutic benefits of dipyridamole in COVID-19 patients","volume":"27","author":"Aliter","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jns.2024.123118_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708665","article-title":"Targeting SARS-CoV-2-platelet interactions in COVID-19 and vaccine-related thrombosis","volume":"12","author":"Cox","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.jns.2024.123118_bb0400","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jns.2024.123118_bb0405","first-page":"9","article-title":"Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors","author":"Motloch","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274243","article-title":"A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection","volume":"18","author":"Singla","year":"2023","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jns.2024.123118_bb0415","first-page":"54","article-title":"Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy","volume":"12","author":"Kalayoglu Besisik","year":"2022","journal-title":"Am J Blood Res"},{"issue":"18","key":"10.1016\/j.jns.2024.123118_bb0420","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1161\/CIRCULATIONAHA.122.061533","article-title":"Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT","volume":"146","author":"Bohula","year":"2022","journal-title":"Circulation"},{"issue":"10320","key":"10.1016\/j.jns.2024.123118_bb0425","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0430","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial","volume":"327","author":"Berger","year":"2022","journal-title":"Jama"},{"issue":"13","key":"10.1016\/j.jns.2024.123118_bb0435","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"327","author":"Bradbury","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2024.123118_bb0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0450","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123118_bb0455","article-title":"Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis","volume":"363","author":"Hao","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jns.2024.123118_bb0460","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123118_bb0465","article-title":"Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline","volume":"363","author":"Prasad","year":"2018","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0470","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.jns.2024.123118_bb0475","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:47:50Z","timestamp":1761785270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":95,"alternative-id":["S0022510X24002533"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123118","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"von Willebrand factor antigen, von Willebrand factor propeptide and ADAMTS13 activity in TIA or ischaemic stroke patients changing antiplatelet therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123118"}}